You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. High-specificity affinity reagents for the detection of glycan sialylation

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    DESCRIPTION provided by applicant Glycans have several distinct properties that make their development as disease biomarkers appealing Firstly their location on cell surfaces makes them the first point of contact for cellular interactions and thus they are crucial in the control of normal metabolic processes and conversely they function as pathogen adhesion receptors Secondly specific gl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Isotopically Labeled Glycoproteins for use as Internal Standards

    SBC: GlycoScientific, L.L.C.            Topic: 300

    DESCRIPTION provided by applicant The ability to accurately quantitate the glycan chains attached to glycoproteins has wide ranging implications Numerous studies over the past years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers and demonstrate the potential of using glycan markers in either a diagnostic or a prognostic manner The glycosylatio ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection

    SBC: MKS Technology            Topic: NIDA

    DESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation

    SBC: Cambium Medical Technologies LLC            Topic: N

    DESCRIPTION provided by applicant Ocular graft versus host disease O GVHD is a particularly severe and debilitating complication of allogeneic hematopoietic stem cell transplantation HSCT O GVHD develops in of patients with chronic GVHD Currently Restasis cyclosporine A is the only FDA approved prescription topical medication to treat O GVHD In Restasis had sales o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Selenium-derivatized New Reagents for Nucleic Acid X-ray Crystallography

    SBC: SENA RESEARCH, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant There are growing demands for D structure determination of nucleic acids and their protein complexes for understanding disease molecule level mechanisms and discovering innovative drugs X ray crystallography is one of the most direct and powerful tools for structure determination of these macromolecules and complexes However the crystallization and phase d ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Anti-CXCL13 mAb to mitigate prostate cancer health disparities

    SBC: JYANT Technologies, Inc.            Topic: NIMHD

    DESCRIPTION provided by applicant The most common metastatic site for hormone refractory prostate cancer HRPC PCa is bone While docetaxel can prolong the overall survival in patients with metastatic HRPC current treatments do not provide a cure Further complicating the matter HRPC is a disease that affects a variety of patients differently which can be problematic for physicians to prov ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Novel adjuvant therapy for triple negative breast cancer

    SBC: JYANT Technologies, Inc.            Topic: 102

    DESCRIPTION provided by applicant Triple negative breast cancer TNBC is very difficult to treat and has no specific targeted therapies Chemotherapies used to treat this disease have many undesirable side effects and patients eventually relapse as a result of chemoresistance Obesity is pandemic in the US and many TNBC suffer from this as well Obesity is accompanied by high levels of leptin ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate Cancer

    SBC: MetCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Castration Resistant Prostate Cancer Castration resistant prostate cancer CRPC directly contributes to patient mortality It is imperative to develop new and effective adjunct therapy to enhance the response of CRPC to hormonal therapy Recently we developed ProFineTM a proprietary formula consisting of bioactive flavonoids enriched in pomegranate fruit and ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of the Antigenicity of Black Restricted FVIII Haplotypes and Haplotype

    SBC: Haplomics            Topic: NIMHD

    Evaluation of the Antigenicity of Black-Restricted Haplotypes of Factor VIII ABSTRACT About 30% of congenital Hemophilia A (HA) patients develop alloantibodies that neutralize the activity of replacement Factor (F) VIII proteins. Such patients, who are termed inhibitor patients, are typically treated with so called bypassing agents such as recombinant (r) FVIIa and FEIBA. Bypassing agents are mor ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. High-specificity affinity reagents for N-glycosylation site mapping and glycomics

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: NIGMS

    DESCRIPTION: Glycans have several distinct properties that make them excellent targets for disease biomarkers. Firstly, the location of the glycans on the cell surface makes them the first point of contact of cellular interactions and thus crucial in thecontrol of normal metabolic processes. Cell surface molecules are also strategically exposed for surveillance by the immune system allowing for t ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government